Your browser doesn't support javascript.
loading
Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes.
Bazzani, Chiara; Filippini, Matteo; Caporali, Roberto; Bobbio-Pallavicini, Francesca; Favalli, Ennio Giulio; Marchesoni, Antonio; Atzeni, Fabiola; Sarzi-Puttini, Piercarlo; Gorla, Roberto.
Afiliación
  • Bazzani C; Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy. bazzani@bresciareumatologia.it
Autoimmun Rev ; 8(3): 260-5, 2009 Jan.
Article en En | MEDLINE | ID: mdl-19027090
OBJECTIVE: To assess the effectiveness of anti-TNFalpha agents by analysing the principal clinical outcomes in patients with active rheumatoid arthritis (RA). METHODS: 1010 patients who received no clinical benefit from previous treatment with methotrexate and/or other DMARDs, were subsequently treated with one or more of the anti-TNFalpha agents. RESULTS: After the first six months of anti-TNFalpha therapy, 29% of the patients showed a good and 47% a moderate European League Against Rheumatism (EULAR) response, and this positive result was maintained after two years of follow-up. Their median Disease Activity Score based on the erythrocyte sedimentation rate and the evaluation of 28 joints (DAS28) decreased from 5.94 at baseline to 4 after six months (p<0.001; Delta 1.94), and further significant responses were also observed after 12, 18 and 24 months; their median 36-month DAS28 score reflected mild disease activity. The median Health Assessment Questionnaire (HAQ) score fell from 1.34 at baseline to 1 after six months of therapy (Delta 0.34; p<0.05), and a further significant reduction was observed during the second and third year of follow up. CONCLUSIONS: Especially when combined with DMARDs, anti-TNFalpha drugs can induce a good clinical response regardless of the particular molecule used, whereas their combination with steroids does not seem to improve disease outcomes at any time during follow-up.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Reumatoide / Inmunoglobulina G / Inmunoterapia Activa / Factor de Necrosis Tumoral alfa / Receptores del Factor de Necrosis Tumoral / Antirreumáticos / Anticuerpos Monoclonales Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Autoimmun Rev Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2009 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Reumatoide / Inmunoglobulina G / Inmunoterapia Activa / Factor de Necrosis Tumoral alfa / Receptores del Factor de Necrosis Tumoral / Antirreumáticos / Anticuerpos Monoclonales Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Autoimmun Rev Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2009 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Países Bajos